Docetaxel with or without estramustine for estramustine refractory castration-resistant prostate cancer: a single institution experience
<p>Abstract</p> <p>Background</p> <p>The significance of combination of docetaxel (DTX) with estramustine phosphate (EMP) in castration-resistant prostate cancer (CRPC) patients remains unclear. In this study, we aimed to retrospectively evaluate the efficacy and toxicity of DTX with or without EMP...
Na minha lista:
| Principais autores: | , , , , , , , , |
|---|---|
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
BMC
2012-02-01
|
| Serier: | BMC Urology |
| Online adgang: | http://www.biomedcentral.com/1471-2490/12/3 |
| Tags: |
Ingen Tags, Vær først til at tagge denne postø!
|
